The in vitro activity of the fluoroquinolone CP-99,219 against gram-positive bacteria was compared with those of five other antimicrobial agents. Against ciprofloxacin-susceptible staphylococci and against streptococci, MICs were <0.12 and .0.5 ,ig/ml, respectively. 219 was also more active than ciprofloxacin against ciprofloxacin-resistant staphylococci, most enterococci, Leuconostoc spp., and lactobacilli. Table 1 . Against ciprofloxacinsusceptible strains of staphylococci, MICs for 90% of isolates tested (MIC90s) of CP-99,219 were '0.12 ,ug/ml, and the new agent was more active than ciprofloxacin and temafloxacin against these strains. Among the ciprofloxacinsusceptible strains of S. aureus, isolates that were methicillin susceptible or resistant demonstrated comparable susceptibilities to CP-99,219. The new drug was the most active quinolone against ciprofloxacin-resistant isolates, but relatively high concentrations were required for inhibition (MIC0s, 8 to 16 ,ug/ml). CP-99,129 was four-to eightfold more active than temafloxacin or ciprofloxacin against streptococci (groups A, B, and G and viridans group streptococci) and pneumococci. Activity of sparfloxacin against these strains fell between that of CP-99,219 and those of ciprofloxacin and temafloxacin. CP-99,219 was fourfold more active than ciprofloxacin against ciprofloxacin-susceptible Enterococcus faecalis (MIC90s, 0.25 to 0.5 ,g/ml) and against both vancomycin-susceptible and -resistant Enterococcus faecium (MIC90s, 4 ,ug/ml). The new quinolone was the most active drug tested against Leuconostoc spp. and Pediococcus spp. and was the most potent quinolone against Corynebacterium jeikeium. Inhibitory concentrations of CP-99,219 against the latter varied over a wide range, however, and were relatively high. Only vancomycin proved to be uniformly active against these strains. There was no difference in the activity against recent isolates of ciprofloxacin-susceptible S. aureus and that against strains collected more than 10 years ago for either CP-99,219 or ciprofloxacin.
against ciprofloxacin-resistant staphylococci, most enterococci, Leuconostoc spp., and lactobacilli.
CP-99,219 is a new fluoroquinolone antimicrobial agent with the chemical designation 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone (3) . As the currently available antimicrobial agents of this class demonstrate relatively modest activities against many gram-positive bacteria (1) , in the present study we evaluated the in vitro activity of CP-99,219 against 370 gram-positive bacteria representing a broad range of antimicrobial resistance patterns.
(This work was presented in part at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., 11 to 14 October, 1992.) Bacterial strains used in this study were recently obtained (1990 to 1991) clinical isolates collected at the Massachusetts General Hospital, with the exception of some strains collected from other sources because of specific or unusual resistance traits. ,B-Lactamase-producing enterococci were recovered earlier in Boston, Mass. (9) , or in Houston, Tex. (8), as described previously. Isolates of Enterococcus avium and Enterococcus raffinosus were referred to our laboratories from various sources (6) Table 1 . Against ciprofloxacinsusceptible strains of staphylococci, MICs for 90% of isolates tested (MIC90s) of CP-99,219 were '0.12 ,ug/ml, and the new agent was more active than ciprofloxacin and temafloxacin against these strains. Among the ciprofloxacinsusceptible strains of S. aureus, isolates that were methicillin susceptible or resistant demonstrated comparable susceptibilities to CP-99,219. The new drug was the most active quinolone against ciprofloxacin-resistant isolates, but relatively high concentrations were required for inhibition (MIC0s, 8 to 16 ,ug/ml). CP-99,129 was four-to eightfold more active than temafloxacin or ciprofloxacin against streptococci (groups A, B, and G and viridans group streptococci) and pneumococci. Activity of sparfloxacin against these strains fell between that of CP-99,219 and those of ciprofloxacin and temafloxacin. CP-99,219 was fourfold more active than ciprofloxacin against ciprofloxacin-susceptible Enterococcus faecalis (MIC90s, 0.25 to 0.5 ,g/ml) and against both vancomycin-susceptible and -resistant Enterococcus faecium (MIC90s, 4 ,ug/ml). The new quinolone was the most active drug tested against Leuconostoc spp. and Pediococcus spp. and was the most potent quinolone against Corynebacterium jeikeium. Inhibitory concentrations of CP-99,219 against the latter varied over a wide range, however, and were relatively high. Only vancomycin proved to be uniformly active against these strains. There was no difference in the activity against recent isolates of ciprofloxacin-susceptible S. aureus and that against strains collected more than 10 years ago for either CP-99,219 or ciprofloxacin.
Against most species we have tested, CP-99,219 was more active than ciprofloxacin and temafloxacin. While the new quinolone was generally more active than sparfloxacin, MIC90s of these two drugs against the more-common patho- 
